Reverdia hires a New Business Development Manager for Europe

Reverdia is the joint venture between Royal DSM and Roquette

Reverdia has appointed Pascal Moritz as the company's Business Development Manager for Europe.

Moritz brings a wealth of experience and a strong industry network to the company. He was previously Business Manager at the bio-based polymers division of Roquette Frères for more than 20 years, in various commercial roles.

Jo Kockelkoren, Reverdia’s Global Commercial Director said: 'We are thrilled to bring such an experienced person into the team. This appointment underlines Reverdia’s long-term commitment to further developing and leading the bio-succinic acid market. We have been producing commercial-scale Biosuccinium in our 10,000 MT capacity plant in Cassano, Italy since 2013. Reverdia has already commercialised, low pH yeast-based succinic acid and also offers access to its patented Biosuccinium technology under licence.'

Reverdia is the joint venture between Royal DSM, the global life sciences and materials sciences company, and Roquette Frères, the global starch and starch-derivatives company. Combining the knowledge and experience of DSM and Roquette, Reverdia produces, sells and licences Biosuccinium.

You may also like

Distribution

2BScientific expands its life science product supply service to Europe with new German facility

The facility in Munich will serve the European market with life science products, including in vitro diagnostic (IVD) reagents, buffers, biomaterials and antibodies
Ingredients

Rousselot and IamFluidics launch dissolvable microcarrier for cell culturing

The alginate and denatured collagen based product allows researchers to produce scalable cell cultures for biologic drugs and cell therapies
Ingredients

Therapeutic: vimseltinib for tenosynovial giant cell tumour

Tenosynovial giant cell tumour (TGCT) is a rare, non-malignant tumour that results from a translocation in the colony stimulating factor 1 (CSF1) gene
Ingredients

Therapeutic: brensocatib for bronchiectasis

The chronic lung disease bronchiectasis is a serious condition in which the bronchi become permanently dilated because of a cycle of infection, inflammation and damage to the lung tissue
Ingredients

Logical Biological expands its raw pharma material development and supply capabilities with new lab

The raw material supplier can now better serve in vitro diagnostic (IVD) manufacturers, as it has a significantly larger operational capacity
Ingredients

Biosynth inaugurates its Biological Technology site in Suzhou, China

The new site will serve the Chinese domestic market, providing raw materials for vaccines and pharmaceuticals, while dealing regional distribution and handling
Manufacturing

New small-scale In-Line mixer range from Silverson Machines

Silverson launches versatile small-scale mixers for pharma and biotech applications
Subscribe now